Tesamorelin / Ipamorelin

Tesamorelin / Ipamorelin is a combination research peptide pairing two distinct growth hormone-axis agents: tesamorelin, a stabilized analog of growth hormone-releasing hormone (GHRH), and ipamorelin, a growth hormone secretagogue characterized in the literature as a ghrelin-receptor agonist. Catalogued here under Weight Loss & Metabolic, the blend is supplied strictly for laboratory research and professional reference use and is not approved by the FDA for therapeutic use. It is offered to licensed practitioners as a reference-grade compound for investigational and educational purposes only.

The pairing is of interest in the research literature because the two constituents are described as acting on complementary nodes of the somatotropic axis, and the combination is studied as a model system for endogenous growth hormone signaling, body-composition research, and metabolic investigation. All statements below are framed as areas of scientific interest rather than established clinical effects; individual results vary, and no therapeutic outcome is claimed or implied.

• Investigated in preclinical and exploratory literature as a model for endogenous growth hormone (GH) and IGF-1 axis signaling
• Studied in research contexts in relation to adipose-tissue and lipid metabolism, including visceral fat distribution
• Examined in body-composition and lean-mass research as an experimental tool compound
• Referenced in metabolic-research literature investigating GHRH analog and growth hormone secretagogue pharmacology
• Explored in investigational settings in relation to downstream markers of the somatotropic pathway

Reference handling information only. Lyophilized peptide is typically stored frozen or refrigerated and kept sealed until use; the unreconstituted vial is generally protected from light, heat, and moisture. For research preparation, the powder is commonly reconstituted with bacteriostatic water (or another suitable sterile diluent), with the diluent added gently against the vial wall and the vial swirled rather than shaken. Reconstituted material is generally held refrigerated, protected from light, and treated as time-limited per standard laboratory practice; freeze-thaw cycling is typically avoided. Always confirm storage parameters against the certificate or label supplied with the specific lot. This is general reference information for storage and handling and is not medical advice; all clinical and research protocols, including any preparation, concentration, or use parameters, are determined solely by the licensed ordering provider at their own discretion.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

The proposed mechanism reflects the complementary pharmacology described for the two constituents acting on the somatotropic axis. Tesamorelin is described in the literature as a stabilized GHRH analog reported to bind GHRH receptors on anterior pituitary somatotrophs, studied for its relationship to pulsatile growth hormone release; ipamorelin is characterized as a growth hormone secretagogue reported to activate the ghrelin/GHS-R1a receptor, and is studied in research for a GH-release profile described as having relatively modest associated effects on cortisol and prolactin signaling. Investigators have explored whether engaging these two upstream pathways in parallel is associated with additive or distinct patterns of GH and downstream IGF-1 signaling relative to either constituent alone. These mechanisms are derived from preclinical and pharmacological research and are presented as proposed rather than established; individual results vary, and no therapeutic outcome is claimed or implied.